ResearcherManisa Celal Bayar UniversityActive in the last 2 years

Atike Pınar Erdoğan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4859-7574; OpenAlex author ID A5030982886. Sources: OpenAlex.

Their work

Papers: 5 (first author 2, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 5

SIRI as a Prognostic Marker in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/medicina61112020 ↗
Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? First author DOI 10.1007/s12029-020-00573-y ↗
Palliative Biliary Drainage Has No Effect on Survival in Pancreatic Cancer: Medical Oncology Perspective. Co-author DOI 10.1007/s12029-021-00754-3 ↗
Pancreatic Cancer Patients Who Cannot Undergo Curative Surgery Live As Much As Patients Over 70 Years Old First author DOI 10.21203/rs.3.rs-150867/v1 ↗
Can Albumin Bilirubin Ratio and Inflammatory Prognostic Index Be A New Marker Determining Survival in Metastatic Pancreatic Cancer? Co-author PMID 35017135 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ferhat Ekinci · 5 shared papers, 2021–2025 · strength 1.05
Hikmet Akar · 1 shared paper, 2025 · strength 0.37
- Paper SIRI as a Prognostic Marker in Metastatic Pancreatic Cancer. DOI 10.3390/medicina61112020 ↗
Mustafa Şahbazlar · 1 shared paper, 2025 · strength 0.37
- Paper SIRI as a Prognostic Marker in Metastatic Pancreatic Cancer. DOI 10.3390/medicina61112020 ↗
Gülcan Bulut · 2 shared papers, 2021–2022 · strength 0.32
- Paper Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? DOI 10.1007/s12029-020-00573-y ↗
- Paper Pancreatic Cancer Patients Who Cannot Undergo Curative Surgery Live As Much As Patients Over 70 Years Old DOI 10.21203/rs.3.rs-150867/v1 ↗
Serkan Yıldırım · 2 shared papers, 2021–2022 · strength 0.32
- Paper Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? DOI 10.1007/s12029-020-00573-y ↗
- Paper Pancreatic Cancer Patients Who Cannot Undergo Curative Surgery Live As Much As Patients Over 70 Years Old DOI 10.21203/rs.3.rs-150867/v1 ↗
Gamze Göksel Ozturk · 1 shared paper, 2022 · strength 0.20
- Paper Palliative Biliary Drainage Has No Effect on Survival in Pancreatic Cancer: Medical Oncology Perspective. DOI 10.1007/s12029-021-00754-3 ↗
Elvina Almuradova · 1 shared paper, 2022 · strength 0.16
- Paper Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? DOI 10.1007/s12029-020-00573-y ↗
Gamze Gökse · 1 shared paper, 2021 · strength 0.16
- Paper Can Albumin Bilirubin Ratio and Inflammatory Prognostic Index Be A New Marker Determining Survival in Metastatic Pancre… PMID 35017135 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.